$16.9 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 102 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TLRY | New | TILRAY INC | $285,494,000 | – | 2,479,515 | +100.0% | 1.69% | – |
| EQIX | New | EQUINIX INC | $263,457,000 | – | 608,600 | +100.0% | 1.56% | – |
| BKNG | New | BOOKING HLDGS INC | $254,488,000 | – | 128,270 | +100.0% | 1.50% | – |
| BPR | New | BROOKFIELD PROPERTY REIT INCcl a | $168,575,000 | – | 8,054,215 | +100.0% | 1.00% | – |
| BABA | New | ALIBABA GROUP HLDG LTDsponsored ads | $61,455,000 | – | 373,000 | +100.0% | 0.36% | – |
| CA | New | CA INC | $61,031,000 | – | 1,382,361 | +100.0% | 0.36% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $55,065,000 | – | 673,500 | +100.0% | 0.32% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $31,494,000 | – | 195,000 | +100.0% | 0.19% | – |
| IDTI | New | INTEGRATED DEVICE TECHNOLOGY | $30,086,000 | – | 640,000 | +100.0% | 0.18% | – |
| New | PTC THERAPEUTICS INCnote 3.000% 8/1 | $21,114,000 | – | 18,350,000 | +100.0% | 0.12% | – | |
| PTCT | New | PTC THERAPEUTICS INC | $19,740,000 | – | 420,000 | +100.0% | 0.12% | – |
| EXEL | New | EXELIXIS INC | $19,138,000 | – | 1,080,000 | +100.0% | 0.11% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $18,799,000 | – | 410,000 | +100.0% | 0.11% | – |
| BPY | New | BROOKFIELD PPTY PARTNERS L Punit ltd partn | $16,595,000 | – | 794,382 | +100.0% | 0.10% | – |
| SLDB | New | SOLID BIOSCIENCES INC | $13,918,000 | – | 295,000 | +100.0% | 0.08% | – |
| ORBK | New | ORBOTECH LTDord | $13,671,000 | – | 230,000 | +100.0% | 0.08% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $11,142,000 | – | 300,000 | +100.0% | 0.07% | – |
| FATE | New | FATE THERAPEUTICS INC | $8,634,000 | – | 530,000 | +100.0% | 0.05% | – |
| ECYT | New | ENDOCYTE INC | $7,104,000 | – | 400,000 | +100.0% | 0.04% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $5,425,000 | – | 250,000 | +100.0% | 0.03% | – |
| New | SOLARCITY CORPnote 2.750%11/0 | $4,932,000 | – | 5,000,000 | +100.0% | 0.03% | – | |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $4,422,000 | – | 200,000 | +100.0% | 0.03% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $4,063,000 | – | 141,815 | +100.0% | 0.02% | – |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $3,653,000 | – | 125,000 | +100.0% | 0.02% | – |
| YMAB | New | Y MABS THERAPEUTICS INC | $3,320,000 | – | 125,000 | +100.0% | 0.02% | – |
| ARQL | New | ARQULE INC | $2,830,000 | – | 500,000 | +100.0% | 0.02% | – |
| RMED | New | RA MED SYS INC | $2,730,000 | – | 150,000 | +100.0% | 0.02% | – |
| STRO | New | SUTRO BIOPHARMA INC | $2,250,000 | – | 150,000 | +100.0% | 0.01% | – |
| New | N/An/a | $0 | – | 0 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 44 | Q2 2024 | 3.7% |
| ALPHABET INC | 35 | Q2 2024 | 4.2% |
| GRIFOLS S A | 35 | Q2 2024 | 0.9% |
| SPDR S&P 500 ETF TR | 34 | Q2 2024 | 27.6% |
| VISA INC | 33 | Q2 2024 | 2.9% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| WABTEC CORP | 30 | Q2 2024 | 3.6% |
| EXELIXIS INC | 30 | Q2 2024 | 3.0% |
| SAVARA INC | 29 | Q2 2024 | 0.3% |
| TRANSUNION | 28 | Q2 2024 | 3.7% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Marblegate Acquisition Corp. | February 01, 2024 | 150,000 | 2.6% |
| Clever Leaves Holdings Inc. | January 23, 2024 | ? | ? |
| SDCL EDGE Acquisition Corp | January 23, 2024 | ? | ? |
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR/A | 2024-08-14 |
| 13F-HR | 2024-08-14 |
| 13F-HR/A | 2024-05-24 |
| 13F-HR/A | 2024-05-15 |
| 13F-HR/A | 2024-05-15 |
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.